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Ideas Montana Medicine Conference
Statement of Senator Max Baucus
November 2, 2007
Introduction
It is great to join you today for the third annual Ideas
Montana Medicine conference. I am thrilled you are
convening again. This conference is about working
together to improve our health and economy. It's about big
ideas and bold new strategies. Our purpose is to support
the innovative work being done right now in Montana.
Thanks again to the Northwest Research and
Education Institute, the Montana Bioscience Alliance, St.
V's Healthcare Foundation, Big Sky EDA and MSU-B for
organizing this conference.
I
Thanks also to the generous sponsors who helped
make this conference possible and everyone else who
contributed.
Irv Weissman
I am pleased that my good friend Irv Weissman is
speaking today. Irv is well-known for his scientific
contributions. But, I have heard the story about his bear
skin rug and how he ate the bear meat raw. Though he is
well-recognized for his scientific achievements, he's still
just a "bear-eater"' from Great Falls. How did a Montana
boy end up at Stanford? Like the rest of us, he was
inspired as a child.
2
When he was 10, Irv read Paul de Kruif's [da-cry-f]
book Microbe Hunters that described the work of Pasteur
and other famous bacteriologists. He became fascinated
by the wonders of science. While Irv was in high school,
he worked in a lab doing transplantation research. By the
time he was 18, Irv had published two papers on cancer
and transplantation.
And Irv continues to approach biomedical research
like a Montana boy. He dreams big and works hard. It's
that vision, ingenuity and "boot strap" mentality that have
lead to his discoveries.
The folks right here in this room are such Montanans.
You are the state's brightest minds and boldest
entrepreneurs. Your ideas are not only changing the
future of health care in our country but they give Montana
its competitive edge.
4
Bioscience Sector in Montana
The bioscience sector is still young in Montana. But,
it shows real promise. We have a growing number of
success stories, like Bacterin [back-ter-rin], LigoCyte [ligo-
site] and Golden Helix. But, the bioscience sector in
Montana is more than that; it's the many scientists,
doctors, and business people across our State that are
driving this industry. Discoveries made at Montana's
universities, institutes and communities are being used to
develop new medicines and therapies, which are saving
lives today. The Montana Bioscience Alliance is evidence
of this diversity and growth.
5
It is exciting. But, it's not without a lot of "elbow
grease." Start-up biotech and biomedical companies face
many unique challenges unlike businesses in other
sectors. These companies often require a lot of capital
upfront and it can take many years before a product
comes to market. This industry is one of the most
research-intensive industries in the world. In 2005, the
biotech sector spent $19.8 billion on research and
development in the U.S alone.
In Montana it is often hard to access the capital
needed to make these novel ideas realities.
6
Many of these companies got their start with the Small
Business Innovation Research Program (SBIR) and Small
Business Technology Transfer (STTR) competitive federal
grant programs. These programs are important
investments in innovation and research and development
of small businesses. Eleven federal
departments participate in the SBIR program and five
departments participate in the STTR program, and they
have awarded $2 billion to small high-tech businesses. In
2007, Montana received 27 SBIR grants, that's a total of
almost $6 million dollars. Since 2001, Montana
companies have received over $60 million dollars in SBIR
grant funds. That's a good start. And I understand you will
be hearing more about these programs today.
7
The state, through the Montana Board of
Commercialization and Development, is supporting these
efforts. In fiscal year 2007, the state invested $2.6 million
in research and commercialization projects.
But, we need a lot more "grease" in Montana to really
make this industry thrive. The public sector can do more
and the private sector needs to be encouraged to invest
more in less obvious places.
8
It can be difficult to draw venture capital (VC) and
angel investors to Montana. Our remoteness, while a
cornerstone of our quality of life, makes both getting
investment in and the "word out," a challenge. But, the
tech centers of today, like San Diego, didn't become that
way overnight. It took the hard work of scientific
visionaries and entrepreneurs.
9
Many of you attended my Economic Development
Summit this spring. There, Ivor Royston spoke on a panel
about bioscience business development. As a founder of
several biomedical companies and a developer of San
Diego's biotech cluster, he understands what it takes.
About thirty years ago, San Diego was a "Montana" to the
bioscience industry. But, now it is a leader. San Diego is
home to more than 500 biomedical companies. Local
universities and research institutions have spun-off at least
192 biotech businesses. In 2004 and 2005, the life
science industry, which includes biotechnology and
medical devices and equipment, attracted $1.4 billion in
venture capital investment to San Diego.
10
There is hope for Montana, but there is a lot of work to
be done. And I believe, we have what it takes to do it.
The purpose of conferences such as this one and the
Economic Development Summit are to foster those efforts.
Today you will hear from Jeremy Lenz, Trent Williams and
Denise Brown about how Minnesota, North Carolina and
Colorado are successfully developing bioscience sectors
in their states. We can learn a lot from what other states
have done and are doing.
11
Bioscience Sector and American Competitiveness
Not only can the life-sciences industry be an important
driver for economic prosperity in our state, but the sector
can help America maintain its competitive edge
internationally. Biotechnology has created more than 200
new therapies and vaccines, including products to treat
cancer, diabetes, HIV/AIDS and other autoimmune
disorders. There are more than 400 biotech drug products
and vaccines currently in clinical trials in the U.S. that
target more than 200 diseases.
As of December 2005, there were over 1,400
biotechnology companies in the U.S., of which 329 were
publicly held.
12
In 2004, life-sciences activities employed 1.2 million
people and generated an additional 5.8 million related
jobs. Bioscience workers earn better wages and often
have higher levels of education.
But, the U.S. is not the only country that recognizes the
benefits of investing in bioscience. China, India and many
other nations view the life-sciences as holding the keys not
only to the discovery of cures for human disease, but to
economic prosperity and dominance.
13
Education is Key
As a society, we need to make the tough choices to
make education a real priority. Many countries are
prioritizing science, math and engineering training. China
is graduating four times more engineers than the U.S.
every year. They have the vision. China is preparing their
workforce to meet not only their own needs, but the
world's needs.
There is a growing shortage of high-tech skilled labor in
America. Between 1980 and 2000, the percentage of
Ph.D. scientists and engineers employed in the United
States who were born abroad increased from 24% to 37%.
Our companies depend on foreign-trained engineers to be
productive and compete.
14
It is critical that not only Montana, but our country, take
these statistics seriously. Our nation's competitiveness
depends upon it.
Last fall, I proposed a comprehensive agenda that
would refocus our educational goals and make the system
better aligned with our twenty-first century needs. It would
emphasize subjects like math, science and computer
science. I proposed full college scholarships for future
teachers of math and science, foreign languages, and
early education instruction. Supplemental wages and
incentives for teachers in rural and underserved areas
would make these subjects more inviting.
15
Investing in early education gets students off to the
right start. I proposed a national voluntary universal pre-
kindergarten education program, with minimum standards
for hours of instruction, teacher qualifications, and
integration with K-through-12 education.
An important part of any proposal is making sure that
education is accessible and affordable. I suggested we
simplify the existing system of federal tax credits for
education, by combining them into a single refundable
Higher Education Credit of up to $2,000 per student for
tuition and other school expenses.
These initiatives are expensive, but necessary. The
cost of doing nothing is even greater.
16
Education is also the key to developing an
entrepreneurial spirit. A recent research review suggests
that there is a link between education and entrepreneurial
performance. This review also shows a correlation
between obtaining a bachelor's degree and the highest
levels of entrepreneurship.
Safe-guarding our technological and scientific
advantage not only makes sense, it's crucial, to America's
competitiveness.
National Institutes of Health
Irv's experience reminds us that politics can stymie
scientific discovery. Let's not let politics hinder our
economic progress. The U.S. continues to stand still while
South Korea, China, Singapore, and India are racing
ahead on the promising field of stem cell research.
17
Likewise, we need to be creative about looking for
ways to support scientific research. I have always been a
strong proponent of the National Institutes of Health (NIH).
This year I voted for a $1 billion dollar increase for NIH
over the 2007 fiscal year level; that would give NIH well
over $29 billion for the next fiscal year. Unfortunately, the
President has indicated that he intends to veto the Labor,
Health and Human Services Appropriations bill.
The days of a sizable federal investment in NIH have
past, at least for the immediate future. It is short-sighted.
Fewer dollars mean fewer scientists and less
commercialization of good technology.
18
Surely, I do not expect the present fiscal climate to
change drastically in the coming years. We need to get-
together and think outside the box. We need to use our
strengths and not fall back on ingrained institutional
approaches.
Conclusion
I stand ready to do all I can to make sure that America
remains competitive and to work with you to build a strong
bioscience sector in Montana.
After all, science is about achieving the unimaginable.
And that's what we must do, not only dare to dream
the impossible, but work together to make it happen.
19
Q&A
With that I turn the floor over to you all.
[There will be about 10 minutes of Q & A]
Welcoming Remarks for Irv Weissman
Thank you all for your time and contributions to
Montana's health and economy.
Now I would like to welcome my good friend, Irv
Weissman. I am sorry that I can not be there with you
today.
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